rosiglitazone has been researched along with sr1664 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Arola, L; del Bas, JM; Garcia-Vallvé, S; Guasch, L; Mulero, M; Ollendorff, V; Pujadas, G; Tomas-Hernández, S | 1 |
| Asteian, A; Blayo, AL; Busby, S; Cameron, MD; Corzo, CA; Garcia-Ordonez, RD; Griffin, PR; He, Y; Kamenecka, TM; Khan, S; Koenig, M; Kumar, N; Kuruvilla, DS; Lin, L; Marciano, DP; Ruiz, C; Shin, Y | 1 |
| Bamberg, K; Bergström, F; Ek, M; Giordanetto, F; Hogner, A; Jianming, L; Johansson, C; Karlsson, D; O'Mahony, G; Petersen, J; Prokoph, N; Rae, R; Zarrouki, B | 1 |
1 review(s) available for rosiglitazone and sr1664
| Article | Year |
|---|---|
Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.
Topics: Animals; Drug Discovery; Humans; Hypoglycemic Agents; Ligands; Phosphorylation; PPAR gamma; Structure-Activity Relationship | 2015 |
2 other study(ies) available for rosiglitazone and sr1664
| Article | Year |
|---|---|
Design, Synthesis, and Biological Evaluation of Indole Biphenylcarboxylic Acids as PPARγ Antagonists.
Topics: | 2015 |
Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARγ Phosphorylation.
Topics: | 2022 |